RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT BETWEEN ISIS PHARMACEUTICALS, INC., AND GLAXO GROUP LIMITEDResearch, Development and License Agreement • May 7th, 2010 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (together with all Appendices and Schedules hereto, the “Agreement”) is entered into as of the 30th day of March, 2010 (the “Effective Date”) by and between ISIS PHARMACEUTICALS, INC., a Delaware corporation, having its principal place of business at 1896 Rutherford Road, Carlsbad, CA 92008 (“Isis”), and GLAXO GROUP LIMITED, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (“GSK”). GSK and Isis each may be referred to herein individually as a “Party” or collectively as the “Parties.” The terms used in this Agreement with initial letters capitalized, whether used in the singular or the plural, will have the meaning set forth in APPENDIX 1.
AMENDMENT #1 TO THE PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENTProduct Development and Commercialization Agreement • May 7th, 2010 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
This AMENDMENT #1 TO THE PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Amendment”) is entered into and made effective as of the 24th day of February 2010 (the “Amendment Date”) by and between Regulus Therapeutics Inc., a Delaware corporation having its principal place of business at 1896 Rutherford Road, Carlsbad, CA 92008 (“Regulus”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (“GSK”). Regulus and GSK are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
EXCLUSIVE LICENSE AND NONEXCLUSIVE OPTION AGREEMENT BETWEEN GLAXO GROUP LIMITED AND REGULUS THERAPEUTICS INC.Exclusive License and Nonexclusive Option Agreement • May 7th, 2010 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
Carlsbad, CA., February 24, 2010 — Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.
SECOND AMENDMENT TO LEASE AGREEMENTLease Agreement • May 7th, 2010 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS SECOND AMENDMENT TO LEASE AGREEMENT (this “Amendment”) is entered into as of this 30th day of March, 2010 (the “Effective Date”), by and between BMR-2282 FARADAY AVENUE LLC, a Delaware limited liability company (“Landlord”), and ISIS PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
